Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can checking blood pressure at home help kidney transplant patients?

NCT ID NCT04364126

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether kidney transplant recipients with high blood pressure could better control their condition by monitoring their blood pressure at home, compared to standard clinic visits. The trial planned to enroll many participants but was stopped early after only 21 people joined. The goal was to see if home monitoring leads to lower blood pressure and better treatment satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Home blood pressure monitoring device
What this could lead to
If successful, this approach could help kidney transplant patients manage their blood pressure more effectively at home, potentially reducing heart risks.
What could go wrong
The trial was terminated early with only 21 participants, so results are limited and may not apply broadly. Home monitoring may not improve outcomes for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Started

Dec 2022

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Kidney transplant recipient 2. Male or female subject ≥ 18 years old 3. Any or more of the following at the baseline clinic * Conventional office BP ≥130 mmHg systolic and/or ≥ 80 mmHg diastolic * HBPM ≥125 mmHg systolic and/or ≥ 80 mmHg diastolic measured within the last 3 months (see appendix 1 for details on methodology) * Daytime ambulatory blood pressure monitoring (ABPM) ≥125 mmHg systolic and/or ≥ 80 mmHg diastolic measured within the last 3 months 4. Signed informed consent and expected cooperation of the patient for the treatment and follow up. 5. Have a national personal identification number and not be expected to emigrate during study 6. Enlisted in the Norwegian Renal Registry Exclusion Criteria: 1. Standing systolic BP \< 110 mmHg (to avoid adverse events). Measured after one and three minutes of standing. Not applicable if unable to stand due to wheelchair use. 2. Diagnosed atrial fibrillation (automated monitors not validated) 3. Unwilling to self-monitor 4. Female participant who is pregnant, lactating or planning pregnancy during the trial (management of essential hypertension in pregnancy is different) 5. Arm circumference too large or small to allow accurate BP measurement with available device (22-42 cm). 6. Any reason likely limiting adherence to interventions, as judged by the investigator; examples include active alcohol or substance abuse within the last 12 months, significant poor compliance with medications or attendance at clinic visits, residence in a nursing home, dementia, other medical or psychiatric conditions that may interfere with study participation. 7. Graft- or life expectancy less than 2 years, as judged by the investigator. 8. Current use of ≥ 4 antihypertensive medications 9. More than half of regular appointments planned as remote (e.g. phone or video) consultations. 10. Severe white-coat hypertension, e.g. patients already treated solely based on home BP values. 11. Multi-organ transplants (e.g. heart, lung, liver), though pancreas or beta-cell islet transplant is allowed.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Oslo University Hospital, Rikshospitalet

    Oslo, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.